Drugs.com - Clinical Trials

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...

Mar 18, 2025 - 07:11
 0
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...
Read More

Tags:

Previous Article

Ulta Beauty Admits Rocky Road Ahead Amid Consumer Uncertainty

Next Article

SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiv...

Related Posts

BioArctic Receives Orphan Drug Designation for Exidavnemab the US

BioArctic Receives Orphan Drug Designation for Exidavne...

Mar 18, 2025  0

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Nurix Therapeutics Receives U.S. FDA Fast Track Designa...

Feb 9, 2025  0

Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity

Spinogenix Completes Phase 2 Study of SPG601 for Treatm...

Feb 13, 2025  0